Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Pemigatinib in Advanced Non-small Cell Lung Cancer With FGFR Alterations
2021-004934-12Phase 2Completed
- Sponsor
- Incyte
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemigatinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Incyte. Primary endpoint: Objective Response Rate in Cohort A. Started Mar 2022; status: completed.
02
Drugs
pemigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004934-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004934-12.